| |
| |
|
| Insider
Information: |
Goldberg Mark Alan |
| Relationship: |
|
| City: |
Lexington |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
79,501 |
|
|
Indirect Shares
|
11,497 |
|
|
| Direct
Value |
$1,729,577 |
|
|
|
Indirect Value
|
$3,065 |
|
|
| Total
Shares |
90,998 |
|
|
| Total
Value |
$1,732,642 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -26.6%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Immunogen Inc |
IMGN |
Director |
2024-02-12 |
0 |
|
0 |
Premium* |
|
|
Synageva BioPharma Corp |
GEVA |
|
2014-09-19 |
562 |
2013-01-02 |
0 |
Premium* |
|
|
Glycomimetics Inc |
GLYC |
|
2024-03-29 |
24,828 |
2024-03-29 |
11,497 |
Premium* |
|
|
Aceragen, Inc |
ACGN |
Director |
2021-01-04 |
38,099 |
2018-12-19 |
0 |
Premium* |
|
|
Audentes Therapeutics, Inc. |
BOLD |
Director |
2020-01-15 |
0 |
2020-01-15 |
0 |
Premium* |
|
|
Blueprint Medicines Corp |
BPMC |
|
2023-06-21 |
16,012 |
2020-06-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
65 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GEVA |
Synageva BioPharma Corp |
SVP, Product Development |
• – – |
2013-01-02 |
4 |
AS |
$47.52 |
$209,896 |
D/D |
(4,417) |
0 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
SVP, Product Development |
• – – |
2013-02-01 |
4 |
AS |
$47.33 |
$210,892 |
D/D |
(4,417) |
0 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
SVP, Product Development |
• – – |
2013-03-01 |
4 |
AS |
$50.39 |
$224,217 |
D/D |
(4,417) |
0 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
SVP,Medical&Regulatory Affairs |
• – – |
2013-04-01 |
4 |
AS |
$54.21 |
$239,831 |
D/D |
(4,416) |
0 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2020-01-15 |
4 |
D |
$60.00 |
$90,000 |
D/D |
(1,500) |
0 |
0 |
- |
|
| IMGN |
Immunogen Inc |
Director |
– • – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(60,720) |
0 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
SVP,Medical&Regulatory Affairs |
• – – |
2013-06-28 |
4 |
A |
$35.68 |
$9,527 |
D/D |
267 |
267 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
SVP,Medical&Regulatory Affairs |
• – – |
2013-10-01 |
4 |
AS |
$63.97 |
$450,203 |
D/D |
(7,000) |
267 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
SVP,Medical&Regulatory Affairs |
• – – |
2013-11-01 |
4 |
AS |
$49.61 |
$349,753 |
D/D |
(7,000) |
267 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
SVP,Medical&Regulatory Affairs |
• – – |
2013-12-03 |
4 |
AS |
$60.49 |
$423,649 |
D/D |
(7,000) |
267 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, Medical & Reg. Strategy |
• – – |
2013-12-31 |
4 |
A |
$36.30 |
$6,970 |
D/D |
192 |
459 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, Medical & Reg. Strategy |
• – – |
2014-06-11 |
4 |
AS |
$80.00 |
$1,727,760 |
D/D |
(21,597) |
459 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, Medical & Reg. Strategy |
• – – |
2014-06-30 |
4 |
A |
$54.89 |
$5,654 |
D/D |
103 |
562 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, Medical & Reg. Strategy |
• – – |
2014-09-16 |
4 |
AS |
$65.01 |
$609,729 |
D/D |
(9,379) |
562 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, Medical & Reg. Strategy |
• – – |
2014-09-17 |
4 |
AS |
$65.06 |
$273,252 |
D/D |
(4,200) |
562 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, Medical & Reg. Strategy |
• – – |
2014-09-19 |
4 |
AS |
$65.24 |
$51,540 |
D/D |
(790) |
562 |
0 |
- |
|
| IMGN |
Immunogen Inc |
Director |
– • – |
2011-11-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
800 |
|
- |
|
| GLYC |
Glycomimetics Inc |
Director |
– • – |
2014-07-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,100 |
|
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-06-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,312 |
1,312 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, Medical & Reg. Strategy |
• – – |
2014-09-19 |
4 |
OE |
$8.73 |
$6,897 |
D/D |
790 |
1,352 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,250 |
3,562 |
0 |
- |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-10-07 |
4 |
AS |
$100.00 |
$545,400 |
D/D |
(5,454) |
3,562 |
0 |
% |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-10-19 |
4 |
AS |
$105.00 |
$572,775 |
D/D |
(5,455) |
3,562 |
0 |
% |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-12-01 |
4 |
AS |
$110.00 |
$599,940 |
D/D |
(5,454) |
3,562 |
0 |
% |
|
| BPMC |
Blueprint Medicines Corp |
Director |
– • – |
2020-12-11 |
4 |
AS |
$115.00 |
$627,325 |
D/D |
(5,455) |
3,562 |
0 |
% |
|
65 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
